C3i Profiled in Outsourced Pharma

C3i CEO Louisa Petropoulos was recently featured in Outsourced Pharma online, discussing the present and future prospects of contract research organizations and Canadian innovation, as… Read More »

Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy

Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.

C3i participates to the challenge Cycle for a Cure!

The 6th edition of the Bike Challenge for Cellular Therapy Research at the Maisonneuve-Rosemont Hospital will give you the opportunity to support scientific work that promotes healing.